Bioretec Oy
Bioretec is a Finnish medical device company that develops and manufactures absorbable orthopedic implants for adult and pediatric fracture fixation. Its product families, Activa and RemeOs™, are designed to support bone healing and then gradually dissolve, reducing the need for implant removal surgery. The company is headquartered in Tampere, Finland, with subsidiaries in Austria and the United States, and sells its products internationally.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueMagnesium alloy orthopedic implants designed to provide fixation and then absorb over time.
Self-reinforced PLGA-based absorbable implants used in orthopedic procedures.
Implants and screws used in trauma and fracture repair applications.
Training, surgeon education, and market development activities tied to product adoption.
Customers
Bioretec sells to hospitals, surgeons, and healthcare systems that perform orthopedic procedures and need fixation devices for fracture healing. The company’s products are used in adult and pediatric orthopedics, with adoption driven by clinical performance, surgeon preference, and the desire to avoid removal surgery. Distribution partners and direct sales channels also matter because they help place the products into local healthcare markets.
Buy absorbable implants for trauma and fracture fixation procedures.
Select Activa and RemeOs™ products based on handling, healing, and removal-avoidance benefits.
Uses absorbable fixation to reduce the need for secondary removal surgery in younger patients.
Buy or represent products in markets outside the U.S. and support local commercialization.
Adopt the products when value-based care and reduced procedure burden are important.
Strategy
Bioretec’s strategy centers on expanding the RemeOs™ platform, generating clinical evidence, and building commercial scale in the U.S. and selected international markets. The company also aims to introduce at least one new product or indication every 12–18 months, using R&D and surgeon engagement to strengthen adoption and support long-term commercialization.
New products and indications broaden the addressable market and deepen the platform.
Direct distribution and surgeon education can improve adoption in the largest target market.
Partner selection and market-specific launches are needed to convert approvals into sales.
Evidence supports surgeon adoption, reimbursement discussions, and regulatory credibility.
Geography
Bioretec is headquartered in Tampere, Finland and operates through subsidiaries in Austria and the United States. Its implants are sold worldwide in more than 40 countries, with commercial priorities centered on the U.S. and selected markets outside the U.S. Geography matters because regulatory approvals, distributor selection, and surgeon education differ by market and directly affect adoption.
Risks
Bioretec depends on regulatory approvals, surgeon adoption, and successful commercialization of a relatively novel implant platform, so execution risk is high. The business also faces typical medtech risks such as product quality, clinical evidence requirements, distributor dependence outside the U.S., and the possibility that adoption of absorbable implants develops more slowly than expected.
- Regulatory and approval riskImpact: HighLikelihood: Medium
Implants must clear country-specific regulatory pathways before sales can expand.
Exposure: RemeOs™ launches and new indications
- Commercial adoption riskImpact: HighLikelihood: Medium
Surgeons may be slow to switch from established metal implants to absorbable alternatives.
Exposure: U.S. direct sales and international launches
- Product quality and clinical riskImpact: HighLikelihood: Low
Implants are used in surgery, so defects or adverse events could affect reputation and approvals.
Exposure - Distributor execution riskImpact: MediumLikelihood: Medium
Outside the U.S., sales depend on partner selection, incentives, and local execution.
Exposure: OUS commercialization
- Innovation pipeline riskImpact: MediumLikelihood: Medium
Growth depends on timely new products and indications from the R&D pipeline.
Exposure: RemeOs™ platform expansion
Accounting
Judgemental itemsSales may be recognized at shipment or delivery depending on contract terms and channel structure.
Impact: Can shift quarterly revenue timing around product launches and distributor orders
R&D for new implant platforms may involve judgment on what can be capitalized versus expensed.
Impact: Affects operating profit and asset balances
If commercialization or approvals lag, related assets may need write-downs.
Impact: Could materially affect earnings and equity
Specialized medical device inventory can become obsolete if product mix or approvals change.
Impact: May create write-downs or margin volatility
Operations span multiple currencies and markets.
Impact: Can affect reported revenue, expenses, and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCAF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026